Impact of tumour burden on chemotherapy-induced nausea and vomiting
1996

Impact of Tumour Burden on Chemotherapy-Induced Nausea and Vomiting

Sample size: 101 publication Evidence: moderate

Author Information

Author(s): TJ Hursti, E Avall-Lundqvist, S B6rjeson, M Fredrikson, CJ First, G Steineck, C Peterson

Primary Institution: Karolinska Institute

Hypothesis

How does residual tumour burden after cytoreductive surgery relate to the occurrence of nausea and vomiting in ovarian cancer patients receiving chemotherapy?

Conclusion

Patients with larger residual tumour burdens experienced more nausea and vomiting after chemotherapy, especially older patients.

Supporting Evidence

  • Patients with large tumour burden reported more delayed emesis, especially on days 2-7.
  • Older patients (>55 years) with large tumour burden had higher occurrences of nausea.
  • Anti-emetic treatment with dexamethasone was a predictor for no delayed emesis.

Takeaway

If you have a bigger tumor left after surgery, you might feel more sick after chemotherapy, especially if you're older.

Methodology

The study involved 101 chemotherapy-naive ovarian cancer patients who self-reported nausea and vomiting for 15 days after their first chemotherapy course.

Potential Biases

Potential biases may arise from self-reported data and the exclusion of patients with severe concurrent diseases.

Limitations

The study did not primarily aim to identify predictors of delayed emesis, and most previous studies were not designed for this purpose.

Participant Demographics

Median age was 54 years, with a range from 18 to 76 years; 68% of patients with large tumour burden were over 55 years old.

Statistical Information

P-Value

0.003

Confidence Interval

1.1-1.9

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication